These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8799087)

  • 21. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
    Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
    Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of screening for colorectal cancer.
    Telford JJ; Levy AR; Sambrook JC; Zou D; Enns RA
    CMAJ; 2010 Sep; 182(12):1307-13. PubMed ID: 20624866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.
    Ladabaum U; Chopra CL; Huang G; Scheiman JM; Chernew ME; Fendrick AM
    Ann Intern Med; 2001 Nov; 135(9):769-81. PubMed ID: 11694102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer.
    Lejeune C; Arveux P; Dancourt V; Béjean S; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2004; 20(4):434-9. PubMed ID: 15609792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of colorectal cancer screening.
    McMahon PM; Bosch JL; Gleason S; Halpern EF; Lester JS; Gazelle GS
    Radiology; 2001 Apr; 219(1):44-50. PubMed ID: 11274533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.
    Vijan S; Hwang EW; Hofer TP; Hayward RA
    Am J Med; 2001 Dec; 111(8):593-601. PubMed ID: 11755501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of colorectal cancer screening in the elderly.
    Wagner JL; Herdman RC; Wadhwa S
    Ann Intern Med; 1991 Nov; 115(10):807-17. PubMed ID: 1929029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Faecal occult blood screening for colorectal cancer: is it cost-effective?
    Whynes DK; Neilson AR; Walker AR; Hardcastle JD
    Health Econ; 1998 Feb; 7(1):21-9. PubMed ID: 9541081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case-control study to evaluate efficacy of screening for faecal occult blood.
    Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
    J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [National colorectal carcinoma screening program deserves further study; a report from the Dutch Health Council].
    van Veen WA
    Ned Tijdschr Geneeskd; 2001 Aug; 145(34):1655-7. PubMed ID: 11552370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of colorectal cancer.
    Winawer SJ
    Surg Oncol Clin N Am; 2005 Oct; 14(4):699-722. PubMed ID: 16226687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness and projected national impact of colorectal cancer screening in France.
    Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
    Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for colorectal cancer: what are the costs?
    Weller D; Moss J; Hiller J; Thomas D; Edwards J
    Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High participation rates are not necessary for cost-effective colorectal cancer screening.
    Howard K; Salkeld G; Irwig L; Adelstein BA
    J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.